We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ligelizumab, Novartis’ investigational anti-IgE antibody, didn’t stand up to the company’s established blockbuster omalizumab in a pair of phase 3 studies in patients with chronic spontaneous urticaria (CSU). Read More
Regeneron and AstraZeneca both say their therapeutic antibody cocktails remain active against Omicron, but questions remain in light of a Chinese study concluding that the variant escapes 85 percent of tested antibodies. Read More
“Epidemiological tracking shows a steep trajectory of new infections, indicating Omicron’s rapid spread but so far with a flatter trajectory of hospital admissions,” said Andrew Noach, Discovery Health’s CEO. Read More
Preliminary results indicate that a Sanofi/GSK booster increased neutralizing antibodies by up to 43-fold, regardless of which vaccines participants originally received. Read More
There are almost 800 drugs for rare diseases either in clinical trials or awaiting review by the FDA, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). Read More
AstraZeneca’s COVID-19 vaccine becomes completely ineffective against the Omicron variant by 15 weeks, according to real-world British data released yesterday. Read More
Adults infected with the Omicron variant are 29 percent less likely to enter the hospital than people infected with other COVID-19 strains, according to the first large-scale real-world clinical data. Read More
Sanofi and GlaxoSmithKline (GSK) said preliminary data from a phase 3 study showed that a booster dose of their experimental COVID-19 shot induces strong immunity but said they won’t release full trial results until early next year. Read More